61
Jianmin Li, David W Robertson: Ureteral stent with drug delivery reservoir. Boston Scientific Scimed, Kacvinsky Daisak Bluni PLLC, February 16, 2016: US09259517

According to one aspect, the invention pertains to a ureteral stent that includes a proximal retention structure configured for retaining the proximal portion in the urinary bladder, which contains a balloon reservoir for storing a pressurized fluid that contains a urologically beneficial drug. In a ...


62
David W Robertson: Devices and methods for minimally invasive reduction of parathyroid adenomas. Boston Scientific Scimed, Bookoff McAndrews PLLC, March 14, 2017: US09592018

Apparatus and methods for performing glandular reduction are described. In an example embodiment, an apparatus includes a needle-like probe containing a scintillation detector for converting gamma and x-rays emitted from a radio-labeled gland into photons that are then carried from the probe through ...


63
David W Robertson, Charles Hanes, Peter Lotze: Expandable member dissection port and related methods. Boston Scientific Scimed, Brake Hughes Bellermann, June 6, 2017: US09669197

Embodiments of the disclosure may include a method for providing access within a patient that may include inserting a medical device through an opening of the patient. The medical device may include an overtube having a lumen and a slot and an elongate member disposed within the lumen of the overtub ...


64
Edward E Beedle, David W Robertson: Anticonvulsant agents. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, July 3, 1990: US04939163

This invention provides certain 4-substituted benzamide derivatives, their pharmaceutical formulations, and their use as anticonvulsant agents.


65
David W Robertson, David T Wong: (R)-norfluoxetine in method for occupying serotonin IC receptors. Eli Lilly and Company, Joseph A Jones, Leroy Whitaker, Robert A Conrad, October 5, 1993: US05250572

The present invention provides (R)-norfluoxetine and pharmaceutically acceptable salts thereof capable of selectively occupying 5HT.sub.1c receptors.


66
Edward E Beedle, David W Robertson: Anticonvulsant agents using cyano dimethylphenyl benzamides. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, May 30, 1989: US04835181

This invention provides certain 4-substituted benzamide derivatives, their pharmaceutical formulations, and their use as anticonvulsant agents.


67
David W Robertson: Bodily implants and methods for delivery and placement of bodily implants into a patients body. Boston Scientific Scimed, Brake Hughes Bellermann, June 21, 2016: US09370412

A method and device for the treatment of fecal incontinence is disclosed. The method includes disposing a bodily implant proximate to an anal canal of a patient. The bodily implant has a strip extending along a length between a first end portion and a second end portion. The strip has a set of first ...


68
Donald R Holland, David W Robertson: Antiarrhythmic method. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, June 5, 1990: US04931470

This invention provides a method of treating or preventing cardiac arrhythmias employing certain 4-amino-N-2,6-(dimethylphenyl)benzamide derivatives.


69
Marlene L Cohen, David W Robertson: Process for preparing pharmaceutical formulation containing ergoline-8-carboxamides derivatives. Elililly And Co, yang jiuchang, July 8, 1998: CN97119578

This invention provides N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides useful for blocking 5HT2 receptors in mammals having an excess of serotonin centrally or peripherally. The invention also provides methods for treating sexual dysfunction, hypertension, migraine, vasospasm, ...


70
David Taiwai Wong, David W Robertson, Donald R Gehlert: N-alkyl-3-phenyl-3-(2-alkylthiophe-noxy) propylamines. Eli Lilly And Co, WANG JINGCHAO YANG HOUCHANG, April 28, 1993: CN92111081

This invention provides N-alkyl-3-phenyl-3-(2-substituted phenoxy)propylamines which are useful to treat neurological disorders associated with norepinephrine imbalance.